

Cardiac I_{Kr} Channels Minimally Comprise hERG 1a and 1b Subunits*

Received for publication, July 23, 2004

Published, JBC Papers in Press, August 10, 2004, DOI 10.1074/jbc.M408344200

Eugenia M. C. Jones, Elon C. Roti Roti, Jinling Wang, Samantha A. Delfosse, and Gail A. Robertson‡

From the Department of Physiology, University of Wisconsin, Madison, Wisconsin 53706

Previous studies suggest native cardiac I_{Kr} channels are composed of alpha subunits encoded solely by the 1a transcript of the *ERG1* gene. Using isoform-specific ERG1 antibodies, we have new evidence that subunits encoded by an alternate transcript, *ERG1b*, are also expressed in rat, canine, and human heart. The ERG1a and -1b subunits associate *in vivo* where they localize to the T tubules of ventricular myocytes. These data indicate native ventricular I_{Kr} channels are heteromers containing two α subunit types, ERG1a and -1b. The hERG1b-specific exon thus represents a novel target to screen for mutations causing type 2 long QT syndrome. These findings also suggest phenotypic analyses of existing type 2 long QT syndrome mutations, especially those exclusive to the hERG1a amino terminus, should be carried out in systems expressing both subunits.

Long QT syndrome (LQTS)¹ is an inherited or acquired disease associated with episodic ventricular arrhythmias and sudden death. One form of inherited LQTS (LQTS-2) results from mutations in the human Ether-a-go-go-Related Gene 1 (*hERG1* or *KCNH2*) (1). *hERG1* encodes a potassium channel with biophysical and pharmacological properties similar to those of cardiac I_{Kr} , thus explaining the underlying cause of LQTS-2 as a defect in this repolarizing current (2, 3). In mammalian heart, two *ERG2* transcripts, *1a* and *1b*, encode proteins differing in their amino-terminal sequence (see Fig. 1A) and gating properties (4, 5). Expressed in *Xenopus* oocytes, these subunits preferentially form heteromultimers (4). However, despite high levels of ERG1b transcript (4), first generation ERG1 antibodies against a common epitope identified only ERG1a protein in native tissue (6, 7), suggesting that ERG1b subunits do not contribute to cardiac I_{Kr} channels. Here we provide the first direct evidence for ERG1b protein expression, localization, and co-assembly with ERG1a in cardiac ventricular myocytes. These findings indicate cardiac I_{Kr} channels are minimally composed of ERG1a and -1b α subunits.

EXPERIMENTAL PROCEDURES

Cell Lines and Antibodies—Human embryonic kidney 293 (HEK-293) cell lines stably expressing wild-type hERG1a have been described

previously (8, 9). Cell lines stably expressing hERG1a and -1b were prepared by transfection of HEK-293/hERG1a stable cells with *hERG1b* containing a Kozak consensus sequence (4) cloned into the BamHI/EcoRI sites of pcDNA3.1z (Invitrogen). Separate cell colonies were selected after plating cells at low density and grown in media containing 100 μ g/ml Zeocin, 500 μ g/ml neomycin for selection. All HEK-293 cells were cultured in Dulbecco's modified Eagle's medium at 37 °C. The pan-ERG1 antibody, ERG1-KA, has been described previously (10). ERG1 isoform-specific antibodies were produced by Bethyl Laboratories (Montgomery, TX) in rabbits. Antisera were affinity-purified using the same peptides employed in immunization. The sequence for the ERG1b peptide is amino acids 12–25 (GALRPPRAQKGRVRR), and the sequence for ERG1a is amino acids 140–153 (SPAHDTNHRGPPPTS) (Neoclone, Madison, WI). In addition, a hERG1a-specific antibody raised in goat (HERG N-20) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish peroxidase-coupled secondary antibodies were purchased from Pierce and Santa Cruz Biotechnology. Fluorophore-coupled secondary antibodies were purchased from Molecular Probes (Lake Oswego, OR). Myosin binding protein C (MyBP-C) was a gift from Drs. Richard Moss and Samantha Harris (University of Wisconsin, Madison).

Cardiac Tissue Preparation—Human male ventricular lysate was purchased from ProSci, Inc. (Poway, CA). Human male ventricular tissue was a gift from Dr. Timothy Kamp, (Dept. of Medicine, University of Wisconsin, Madison). Canine ventricular myocytes, a gift from the laboratory of Dr. Rob Haworth (Dept. of Surgery, University of Wisconsin, Madison), were isolated from mongrel males and enzymatically treated as previously described (11). Sprague-Dawley rat ventricles were excised from anesthetized adult males after injection of sodium pentobarbital (100 mg/kg body weight intraperitoneal) as described previously (11). Rat ventricular myocytes were prepared using the same procedure as described for the canine tissue. All procedures have been approved by the Research Animal Resources Center at University of Wisconsin, Madison.

Cell Membrane Protein Preparations—Membranes were prepared from myocytes or ventricular tissue after suspension in homogenization buffer (25 mM Tris-HCl, pH 7.4, 10 mM NaEGTA, 20 mM NaEDTA). All buffers used in this procedure contained the following protease inhibitor mixture: 5 μ g/ml aprotinin, 50 μ g/ml 1,10-phenanthroline, 0.7 μ g/ml pepstatin A, 1.56 μ g/ml benzamidine, and 1 \times Complete minitab (Roche Applied Science). Suspensions were homogenized using a Polytron homogenizer at setting 6 for two bursts of 15 s each followed by sonication on ice twice at an amplitude of 20 for 20 s each. Suspensions were spun at 2,000 \times g at 4 °C for 10 min to remove cellular debris. The supernatants were subject to further centrifugation at 40,000 \times g for 30 min at 4 °C. The resultant pellet was solubilized on a rotary shaker at 4 °C for 2 h in either Triton buffer (150 mM NaCl, 25 mM Tris-HCl, pH 7.4, 20 mM NaEDTA, 10 mM NaEGTA, 5 mM glucose, and 1% (v/v) Triton X-100), or RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1 mM NaEDTA, and 1% (v/v) Triton X-100, 1% (v/v) sodium deoxycholate, 0.1% (v/v) sodium dodecylsulfate). Samples were then spun at 10,000 \times g to remove insoluble material. Cell line membrane pellets were prepared by washing plates gently with PBS, aspirating, and adding either Triton buffer or RIPA buffer. Cells were then scraped, collected in a microcentrifuge tube, and sonicated on ice twice at an amplitude of 20 for 20 s each. The suspension was rotated at 4 °C for 2 h and then centrifuged at 10,000 \times g for 10 min to remove insoluble material. Protein concentrations of all samples were determined using a modified Bradford assay (DC Protein Assay, Bio-Rad).

* This research was supported by National Institutes of Health Grant R01 HL68868 (to G. A. R.) and Training Grant T32 HL07936 (to E. C. R. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ To whom correspondence should be addressed. Tel.: 608-265-3339; Fax: 608-265-5512; E-mail: Robertson@physiology.wisc.edu.

¹ The abbreviations used are: LQTS, long QT syndrome; HEK, human embryonic kidney; PBS, phosphate-buffered saline.

² The human isoform is termed hERG; ERG is the more general term applied to lower mammals.

Biochemical Analysis—Membrane proteins were deglycosylated using PNGase F and endoglycosidase H (Roche Applied Science) as described previously (8, 12). Proteins were denatured at 60 °C to avoid thermal aggregation at higher temperatures. To determine which proteins were expressed on the surface membrane, proteins were surface-biotinylated using sulfo-NHS-LC-Biotin reagent as described previously (10). Briefly, 100 mm tissue culture dishes with growth at 70–80% confluency were rinsed three times with cold PBS and incubated with freshly prepared biotin reagent (5 mg/ml) in PBS for 45 min at 4 °C. Cells were then rinsed once with 25 mM Tris-HCl, pH 7.5, to quench the reaction, followed by three washes with cold PBS. Membrane proteins were prepared as indicated above.

Western Blot Analysis—Membrane proteins (cell lines 2–10 µg/lane, heart lysates 30–50 µg/lane) were electrophoresed on 7.5% SDS-polyacrylamide gels along with prestained molecular weight markers (Bio-Rad) and then transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore, Bedford, MA) for 1 h at 100 mV. Western blots were blocked, probed, and analyzed as described earlier (10). For peptide block experiments 5 µl of antibody was incubated with 10 µg of peptide in 100 µl of TBS (150 mM NaCl, 25 mM Tris-HCl, pH 7.4) for 6 h at 4 °C and then centrifuged at 10,000 × *g* for 20 min. The supernatant was carefully removed and used to probe Western blots. Western blot controls include probing blots with secondary antibody alone and peptide block of primary antibody. In the case of heart lysates, a lane containing hERG1a/1b cell membrane preparation was included as a positive control.

Co-immunoprecipitation—Membrane lysates (cell lines 100–200 µg/reaction, heart lysates 500–1000 µg/reaction) in 1 ml of TBS were cleared with 50 µl of protein A- or G-Sepharose beads (Amersham Biosciences) depending on the origin of the immunoprecipitating antibody; protein A was used for rabbit and protein G for goat immunoprecipitating antibodies. Cleared lysates were incubated with antibody (ERG1b at 1:100 or N-20 at 1:20) on a rotating platform for 3–16 h at 4 °C. 50 µl of protein A- or G-coupled beads were added and samples were incubated at 4 °C for an additional 1–3 h. Beads were collected by centrifugation at 10,000 × *g* and washed three times with 150 mM NaCl, 25 mM Tris-HCl, pH 7.4, 5 mM NaEDTA, 1% (v/v) Triton X-100, followed by one wash with 150 mM NaCl, 25 mM Tris-HCl, pH 7.4. Proteins were eluted with 200 ng/ml antibody-specific peptide for 1 h at 4 °C. Samples were centrifuged at 10,000 × *g*, and the supernatant was collected. 100 µl of LSB (25 mM Tris-HCl, pH 6.8, 2% (v/v) sodium dodecylsulfate, 10% glycerol) was added to the beads to elute any proteins that remained bound. Additional controls included lysates processed without antibody. Eluted proteins were Western blotted as described above.

Immunohistochemistry—Isolated canine myocytes were fixed in 2% paraformaldehyde-PBS, pH 7.4, for 10 min at room temperature and washed three times in PBS, pH 7.4. Myocytes were then either stored at 4 °C (for up to 8 weeks) or processed immediately. Myocytes were washed once in PBS, pH 7.4, + 1% Triton X-100 and permeabilized in PBS, pH 7.4, + 0.5% Triton X-100 for 10 min at room temperature followed by incubation in 0.75% glycine-PBS (pH 7.4) for 10 min at room temperature to quench any free aldehydes and incubation in blocking buffer (PBS, pH 7.4, + 0.1% Tween-20 + 10% donkey serum + 2% bovine serum albumin) for 2 h at 4 °C with rotation. Cells were washed three times with PBS, pH 7.4, + 0.1% Tween-20 and divided into 0.5-ml aliquots. Each myocyte aliquot was incubated overnight at 4 °C in diluted primary antibody. ERG1b antibodies were diluted 1:1000, ERG1a antibodies (N-20) were diluted 1:10, and myosin binding protein C antibodies were diluted 1:500. Myocytes were washed three times for 1 h in PBS, pH 7.4, + 0.1% Tween-20. Secondary antibodies were diluted in PBS, pH 7.4, + 0.1% Tween-20, + 5% bovine serum albumin, and spun to remove any aggregates. Myocytes were suspended in 0.5 ml of diluted secondary antibody and incubated in the dark 2 h at room temperature with rotation. Donkey anti-rabbit Alexa 488 and donkey anti-goat Alexa 568 antibodies were diluted 1:1000. Myocytes were washed briefly 3x with PBS, pH 7.4, + 0.1% Tween-20 followed by two 1-h washes with PBS, pH 7.4, and were stored at 4 °C until viewed on a Zeiss Axiovert 200 microscope with a ×63 objective. Optical sectioning was accomplished using the Apotome, and three-dimensional rendering was conducted within Axiovision software. Fluorescent excitation-emission filter set for Alexa 488 (excitation 450–490 nm, emission 515–565 nm) and Alexa 568 (excitation 500–639 nm, emission 560–700 nm) do not overlap. Species specificity of secondary antibodies was confirmed by incubating cells probed with one primary with secondary antibody raised against the other species. No signal was detected demonstrating each second-




FIG. 1. ERG1 expression in rat ventricular myocytes. A, schematic topology of ERG1a and -1b amino-terminal regions showing divergent amino termini (hatched) and identical regions (white and black). Predicted molecular mass for ERG1a is 127 kDa, and predicted molecular mass for ERG1b is 90 kDa. B, representative Western blot of 40 µg of membrane proteins isolated from rat ventricular myocytes, separated by SDS-PAGE on an 8% gel, was probed with ERG1-KA antiserum. Three distinct bands were present at 160 kDa, 120 kDa, and 95 kDa ($n = 7$).

ary is species specific. Secondary alone controls were also used to ensure the signal was specific.

RESULTS

We initially observed an ERG1b-sized band on a Western blot of rat heart tissue when we probed with a novel, carboxyl-terminal ERG1 antibody termed KA, generated as a tool for a related study (10). As shown in Fig. 1B, the ERG1-KA antibody identified three bands at 160, 120, and 95 kDa. The two higher molecular mass bands are consistent in size with maturely glycosylated and unglycosylated rat ERG1a, respectively (6). The 95-kDa band is consistent in size with ERG1b protein produced in heterologous expression systems (see below) but not observed previously in native tissue. The 95-kDa band cannot represent *ERG-USO*, another *hERG1* transcript that produces a protein of approximately the same size (13) because *ERG-USO* does not contain the carboxyl-terminal sequence against which the ERG1-KA antibody was raised.

To test the hypothesis that the 95-kDa band represents ERG1b, we generated antibodies specific to the ERG1a and ERG1b amino termini. Fig. 2 shows the characterization of the two antisera and the pan-ERG1 antibody ERG1-KA on Western blots of membrane proteins prepared from HEK-293 cells stably expressing hERG1a and -1b. The ERG1-KA antibody recognized bands at 155 and 135 kDa, consistent with previously published results identifying these bands as mature and immature hERG1 glycoforms, respectively (Fig. 2A, Lane 1) (8). In addition, ERG1-KA recognized three lower molecular mass bands at 95, 85, and 80 kDa. The 95- and 85-kDa bands are consistent with bands attributed to hERG1b in tumor cell lines (14) and heterologously expressed in QT-6 cells (6).

As expected, blots probed with the ERG1a-specific antibody recognized the 155- and 135-kDa bands but not the three lower-mass bands (Fig. 2A, Lane 2). The 155- and 135-kDa bands were eliminated upon incubation of the ERG1a antisera with




FIG. 2. A, ERG1a and ERG1b-specific antisera characterization. Western blots of membrane proteins from HEK-293 cells stably expressing hERG1a and -1b (4 μ g/lane, $n = 3$). Molecular weight markers, in kDa, are indicated. *Lane 1*, ERG1-KA antibody (1/5000) recognizes 155-, 135-, 95-, 85-, and 80-kDa bands. *Lane 2*, ERG1a-specific antibody (1/100) confirming the 155- and 135-kDa bands in *Lane 1* represent hERG1a. *Lane 3*, ERG1a antibody preincubated with 1a-peptide shows no bands. *Lane 4*, ERG1b-specific antibody confirms that the lower 95-, 85-, and 80-kDa bands represent hERG1b. *Lane 5*, ERG1b-specific antibody preincubated with 1b-peptide shows no bands. B, ERG1b glycosylation states and surface expression ($n = 4$). Western blots of HEK-293 ERG1a/1b stable cell line membrane protein preparations probed with ERG1-KA antibody. *Lane 1*, 2 μ g of membrane protein shows predominantly 95- and 85-kDa bands and a faint shadow at 80 kDa. *Lane 2*, 10 μ g of membrane preparation following PNGase F treatment shows an 80-kDa band. *Lane 3*, 10 μ g of membrane preparation following endoglycosidase H treatment shows bands at 95 and 80 kDa. *Lane 4*, 10 μ g of streptavidin purified proteins from surface-biotinylated cells shows only the 95-kDa ERG1b band is on the surface.

the antigenic 1a peptide prior to probing the blots (*Lane 3*). The ERG1b-specific antibody recognized the 95-, 85-, and 80-kDa bands but not the two higher mass hERG1a bands (*Lane 4*). These bands were similarly eliminated by preincubation of the antisera with the antigenic 1b peptide (*Lane 5*). These data show that ERG1-KA antisera recognize both 1a and 1b isoforms and that ERG1a and -1b antisera are specific for their corresponding isoforms.

Membrane proteins from stable HEK-293 hERG1a/1b cell lines were incubated with glycosidases to determine whether the multiple hERG1b bands on Western blots correspond to different glycoforms as shown previously for the hERG1a 155- and 135-kDa bands (8). Removing all glycans from the hERG1b proteins by incubating membrane preparations with PNGase F reduced the higher molecular mass hERG1b species to a single 80-kDa band (Fig. 2B, *Lane 2*). Digestion with endoglycosidase H, which removes only glycans that are attached in the endoplasmic reticulum but not yet processed in the Golgi, reduced the 85-kDa band to 80-kDa but left the 95-kDa band unaltered (Fig. 2B, *Lane 3*). Thus, the 95-kDa band represents the maturely glycosylated (Golgi processed) hERG1b isoform, the 85-kDa band represents the core glycosylated, endoplasmic reticulum-retained form, and the 80-kDa band represents the unglycosylated form. To determine whether the mature hERG1b glycoform is expressed on the cell surface, where it could contribute to hERG1 currents, surface proteins were biotinylated prior to cell lysis. Biotinylated proteins were affinity purified with streptavidin beads, blotted, and probed with ERG1-KA antisera. Like hERG1a, only the maturely glycosylated hERG1b (95-kDa) protein band was biotinylated (Fig. 2B,




FIG. 3. ERG1b expression *in vivo*. Representative Western blots of 25 μ g of membrane proteins from human and canine ventricular myocytes were size-separated by SDS-PAGE on a 7.5% gel and probed with either ERG1-KA, ERG1a, or ERG1b antisera. Molecular masses are indicated on the left of each blot. A, human ventricular membrane proteins. *Lane 1*, probed with ERG1-KA antisera, exhibits bands at 140, 120, 94, and 83 kDa. *Lane 2*, probed with 1b-specific antisera, exhibits prominent bands at bands at 94 and 83 kDa. In the example shown additional bands at 102 and 98 kDa are present. Although these are not visible on Western blots probed with ERG1-KA, they are blocked by preincubation of antibody with the 1b peptide, suggesting that they are hERG1b isoforms possibly modified posttranslationally ($n = 2$ adult male individuals). B, canine ventricular membrane proteins. *Lane 1*, probed with KA antisera, shows bands at 160, 140, and 95 and a weak band at 83 kDa. *Lane 2*, probed with 1a-specific antisera, shows bands at 160 and 140 kDa. *Lane 3*, probed with 1b-specific antisera, shows bands at 95 and 83 kDa ($n = 11$).

Lane 4), showing hERG1b is expressed on the cell surface in HEK-293 cells.


Next we tested the hypothesis that the lower molecular mass signals observed in native cardiac tissue correspond to the ERG1b protein using the ERG1a- and -1b-specific antisera. In Western blots from two separate human ventricular membrane preparations, the ERG1-KA antibody revealed bands at 140, 120, 94 and 83 kDa (Fig. 3A, *Lane 1*). The 140- and 120-kDa bands are consistent with previous reports from human tissue (6) and represent the maturely glycosylated and unglycosylated hERG1a, respectively. The 1b-specific antibody recognized the 94- and 83-kDa bands (Fig. 3A, *Lane 2*) demonstrating that ERG1b protein is expressed in human ventricle.

ERG1b was also observed in canine ventricular tissue. There the ERG1-KA antibody consistently recognized proteins at 160–165 and 90–95 kDa and less consistently at 140–145, 115–125, and 80–85 kDa. Fig. 3 shows that high molecular weight bands at 165 and 140 kDa were recognized by both ERG1-KA and ERG1a antibodies and thus represent ERG1a isoforms (Fig. 3B, *Lanes 1* and 2). The ERG1b antibody recognized the bands at 95 and 83 kDa, which were also recognized by ERG1-KA, demonstrating that these bands represent ERG1b isoforms (Fig. 3B, *Lanes 1* and 3). These data show conclusively that both ERG1a and -1b proteins are expressed within the ventricle across a range of mammalian species.

To determine whether ERG1a and -1b are associated in native tissue, bidirectional co-immunoprecipitations were carried out in four separate canine cardiac membrane preparations. Fig. 4A shows that ERG1a protein was co-immunoprecipitated with the ERG1b-specific antibody and that ERG1b protein was co-immunoprecipitated with the ERG1a-specific antibody. Similar results were obtained from membrane preparations of human myocytes immunoprecipitated with ERG1a-specific antibody (data not shown). These data show ERG1a and -1b proteins associate in mammalian ventricular myocytes *in vivo*.

Consistent with their biochemical association, ERG1a and ERG1b signals localized to the same subcellular compartment using immunocytochemistry. Both the 1a and 1b antibody in fixed, permeabilized canine myocytes revealed a punctate, Z-line-like fluorescence pattern characteristic of a T tubular lo-

FIG. 4. **ERG1a and -1b are associated in cardiac myocytes.** *A*, representative Western blot of canine myocyte membrane preparation with amino-terminal-specific antibody. The ERG1b antibody immunoprecipitated a 160-kDa 1a band, and the ERG1a antibody immunoprecipitated a 85-kDa 1b band ($n = 4$). *B–F*, immunohistochemistry of canine ventricular myocytes. *B*, myocytes probed with 1a-specific antibody and (*C*) 1b-specific antibody show Z line-like staining. *D–F*, concurrent localization of myosin binding protein C (*green*) and ERG1a protein (*red*). MyBP-C protein localizes to the A-band region (*D* and *E*) at the interior of the myocyte as expected. ERG1a staining is limited to the I-band region, adjacent to the A-bands (*D* and *E*) and extends from the cell surface toward the interior (*F*).



calization (Fig. 4, *B* and *C*) (11). To characterize ERG1 localization more precisely, we stained myocytes concurrently with ERG1a and myosin binding protein C (MyBP-C) antisera (15). Three-dimensional images were rendered from a stack of deconvolved two-dimensional immunofluorescent images. MyBP-C signal, in *green*, appeared as a repeating pattern of *doublets* separated by regions devoid of fluorescence that span the width of the cell (Fig. 4, *D–F*). MyBP-C signal localizes to the myosin-containing sarcomere A-band (16); the *unstained areas*, between *doublets*, represent M-lines (Fig. 4*E*). ERG1a fluorescent signal, shown in *red*, is seen in *I-bands* adjacent to *A-bands* (Fig. 4, *D* and *E*). Both Z lines and T tubules are located in the I-band (17). The punctate *red* ERG1a signal extends in columns from the cell surface to the interior, as expected of a T tubular-restricted protein, where it borders the *green* MyBP-C signal (Fig. 4*E*). These data indicate ERG1 signal in canine myocytes is consistent with a T tubular distribution.

DISCUSSION

In this study, we have shown ERG1b protein is produced in mammalian heart. The absence of ERG1b protein in previous studies is likely attributable to a lower affinity of the antibodies employed and/or differential accessibility to the common epitope in ERG1a and -1b. Studies by Finley *et al.* (7) in equine and Rasmussen *et al.* (18) in rat mention the appearance of an ~100-kDa band in some preparations of cardiac membranes. In retrospect, it is reasonable to suggest these signals represented early indications of the ERG1b isoform.

We also show ERG1a and -1b proteins are associated in ventricular myocytes. In heterologous systems, ERG1a and -1b expression produces currents with biophysical properties that

cannot be explained by the coexistence of two populations of homomeric channels (4). The properties of these heteromeric channels more closely resemble those of native I_{Kr} channels (19). Localization of ERG1a and -1b to T tubular structures in canine ventricular myocytes is consistent with electron microscopy studies in rat myocytes showing ERG1 protein predominantly localized to the T tubules where it could regulate action potential duration at the site of excitation-contraction coupling (20). These data strongly suggest native I_{Kr} channels, which are localized to T tubules, comprise both ERG1a and -1b subunits.

Understanding cardiac I_{Kr} physiology and the disease mechanisms of *hERG*-linked congenital and acquired LQTS necessitates approximating the native state in heterologous systems as closely as possible, minimally requiring coexpression of hERG1a and -1b. In addition, our findings have significant implications for amino-terminal mutations causing LQTS. Approximately 20% of LQTS-2 mutations reside in the amino terminus of hERG1a (pc4.fsm.it:81/cardmoc/hergmut.htm), where they can truncate the protein, alter gating properties, and/or cause trafficking deficiencies (21–25). Because *ERG1a* and -1b are alternate transcripts produced by the *ERG1* gene, mutations in exons encoding the ERG1a amino terminus are not likely to affect the production of wild-type ERG1b from this gene. These findings argue for screening LQTS patients for mutations in the *hERG1b*-specific exon and assessing the disease mechanism of all mutations in heterologous expression systems in which hERG1a and -1b are co-expressed.

Acknowledgments—We thank members of the Robertson lab for support and helpful discussions, Dr. Barry London for assistance with antibodies, Dr. Robert Haworth for canine heart tissue, Dr. Tim Kamp

for human heart tissue, Drs. Rick Moss and Samantha Harris for MyBP-C antibodies, Drs. Craig January and Eugene Kaji for tissue culture space, and Drs. Cindy Czajkowski, Craig January, and Jeff Walker and members of their laboratory for helpful discussions.

REFERENCES

- Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., and Keating, M. T. (1995) *Cell* **80**, 795–803
- Sanguinetti, M. C., Jiang, C., Curran, M. E., and Keating, M. T. (1995) *Cell* **81**, 299–307
- Trudeau, M. C., Warmke, J. W., Ganetzky, B., and Robertson, G. A. (1995) *Science* **269**, 92–95
- London, B., Trudeau, M. C., Newton, K. P., Beyer, A. K., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Satler, C. A., and Robertson, G. A. (1997) *Circ. Res.* **81**, 870–878
- Lees-Miller, J. P., Kondo, C., Wang, L., and Duff, H. J. (1997) *Circ. Res.* **81**, 719–726
- Pond, A. L., Scheve, B. K., Benedict, A. T., Petrecca, K., Van Wagoner, D. R., Shrier, A., and Nerbonne, J. M. (2000) *J. Biol. Chem.* **275**, 5997–6006
- Finley, M. R., Li, Y., Hua, F., Lillich, J., Mitchell, K. E., Ganta, S., Gilmour, R. F., and Freeman, L. C. (2002) *Am. J. Physiol.* **283**, H126–H138
- Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J. C., Robertson, G. A., and January, C. T. (1998) *Biophys. J.* **74**, 230–241
- Furutani, M., Trudeau, M. C., Hagiwara, N., Seki, A., Gong, Q. M., Zhou, A. F., Imamura, S., Nagashima, H., Kasanuki, H., Takao, A., Momma, K., January, C. T., Robertson, G. A., and Matsuoka, R. (1999) *Circulation* **99**, 2290–2294
- Roti Roti, E. C., Myers, C. D., Ayers, R. A., Boatman, D. E., Delfosse, S. A., Chan, E. K. L., Ackerman, M. J., January, C. T., and Robertson, G. A. (2002) *J. Biol. Chem.* **277**, 47779–47785
- He, J. Q., Conklin, M. W., Foell, J. D., Wolff, M. R., Haworth, R. A., Coronado, R., and Kamp, T. J. (2001) *Cardiovasc. Res.* **49**, 298–307
- Zhou, Z., Gong, Q., Epstein, M. L., and January, C. T. (1998) *J. Biol. Chem.* **273**, 21061–21066
- Kupershmidt, S., Snyders, D. J., Raes, A., and Roden, D. M. (1998) *J. Biol. Chem.* **273**, 27231–27235
- Crociani, O., Guasti, L., Balzi, M., Becchetti, A., Wanke, E., Olivetto, M., Wymore, R. S., and Arcangeli, A. (2003) *J. Biol. Chem.* **278**, 2947–2955
- Harris, S. P., Bartley, C. R., Hacker, T. A., McDonald, K. S., Douglas, P. S., Greaser, M. L., Powers, P. A., and Moss, R. L. (2002) *Circ. Res.* **90**, 594–601
- Craig, R., and Offer, G. (1976) *Proc. R. Soc. Lond. B. Biol. Sci.* **192**, 451–461
- Huxley, A. F., and Niedergerke, R. (1954) *Nature* **173**, 971–973
- Rasmussen, H. B., Moller, M., Knaus, H. G., Jensen, B. S., Olesen, S. P., and Jorgensen, N. K. (2004) *Am. J. Physiol.* **286**, H1300–H1309
- Yang, T., Wathen, M. S., Felipe, A., Tamkun, M. M., Snyders, D. J., and Roden, D. M. (1994) *Circ. Res.* **75**, 870–878
- Brette, F., and Orchard, C. (2003) *Circ. Res.* **92**, 1182–1192
- Chen, J., Zou, A., Splawski, I., Keating, M. T., and Sanguinetti, M. C. (1999) *J. Biol. Chem.* **274**, 10113–10118
- Larsen, L. A., Andersen, P. S., Kanters, J., Svendsen, I. H., Jacobsen, J. R., Vuust, J., Wettrell, G., Tranebjærg, L., Bathen, J., and Christiansen, M. (2001) *Clin. Chem.* **47**, 1390–1395
- Paulussen, A., Raes, A., Matthijs, G., Snyders, D. J., Cohen, N., and Aerssens, J. (2002) *J. Biol. Chem.* **277**, 48610–48616
- Delisle, B. P., Anderson, C. L., Balijepalli, R. C., Anson, B. D., Kamp, T. J., and January, C. T. (2003) *J. Biol. Chem.* **278**, 35749–35754
- Delisle, B. P., Anson, B. D., Rajamani, S., and January, C. T. (2004) *Circ. Res.* **94**, 1418–1428